Cover Image
市場調查報告書

循環腫瘤細胞 (CTC) 及癌症幹細胞 (CSC) 的市場

The Market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs)

出版商 Kalorama Information 商品編碼 279333
出版日期 內容資訊 英文 204 Pages
訂單完成後即時交付
價格
Back to Top
循環腫瘤細胞 (CTC) 及癌症幹細胞 (CSC) 的市場 The Market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs)
出版日期: 2015年06月19日 內容資訊: 英文 204 Pages
簡介

本報告提供基於循環腫瘤細胞(CTC)的各種技術及其可能性調查,提供您癌症及循環腫瘤細胞 (CTC) 概要,現在及未來的CTC標記,現在及未來的CTC的臨床性用途,CTC的各種分離·檢測·回收技術,產業結構,影響市場的各種趨勢,企業及企業間的配合措施,用途·各地區的市場收益的變化與預測,並彙整主要企業的簡介等資訊。

第1章 摘要整理

第2章 癌症概要

  • 疾病概要
  • 風險因素
  • 盛行率·發病率

第3章 循環腫瘤細胞 (CTC) 概要

  • 概要
  • CTC的用途
  • CTC的特徵
  • CTC的特定·分析用目前標記
    • EpCAM
    • EpB4
    • EGFR
    • HER2
    • MUC-1
    • CEA
    • Cytokeratins
  • 臨床用途研究中的其他CTC標記
    • Cyclophilins
    • Plastin3 (PLS3)
    • Vimentin
    • 總論
  • 現在·未來的CTC臨床用途
    • 生存預測工具
    • 癌症的非侵入性初期診斷
    • 疾病的轉變·轉移力預測
    • 治療的指導與監測·治療效果的預測材料
    • 臨床試驗上患者的層別化
    • 臨床試驗的替代試驗指標
    • 藥物開發:藥物標的選擇

第4章 CTC分離·檢測技術

  • 概要
  • 物理特性式濃縮法
    • 以尺寸為準
    • 以濃度為準
    • 電生理學式
  • 免疫中介性的回收法
    • 免疫磁平台
    • 微流體平台
    • 總論
  • 光學的特定·表示
    • Bioview的Duet Cell Imaging System (以色列)
    • CytoTrack的Optical Scanning Technology (丹麥)
    • Epic Sciences (美國)
    • Ikonisys (美國)
  • 核酸式的CTC檢測法
    • RNAscope (Advanced Cell Diagnostics:美國)
  • 細胞數檢測的檢測·表示
    • FASTcell Cytometer (SRI Biosciences:美國)
    • On-chip Sort Cell Sorter (晶載Biotechnologies:日本)
  • 其他CTC分離·檢測技能方法

第5章 產業·市場形勢

  • 產業結構
  • 競爭因素
  • 產品分析
    • CellSearch
    • AdnaTests
  • 主要市場趨勢
  • 產業上主要事件
  • 整體市場收益與其預測
    • 市場概要
    • 整體市場預測

第6章 企業簡介

  • Janssen Diagnostics
  • AdnaGen AG (現在QIAGEN Hannover GmbH)
  • Acousys Biodevices, Inc.
  • Advanced Cell Diagnostics, Inc.
  • ApoCell, Inc.
  • BioCEP Ltd.
  • Biocept, Inc.
  • Biofluidica
  • BioView Ltd.
  • Clearbridge Biomedics Pte Ltd
  • Creatv MicroTech, Inc.
  • Cynvenio Biosystems
  • CytoTrack ApS
  • DeNovo Sciences Inc.
  • Epic Sciences
  • Fluidigm Corporation
  • Fluxion Biosciences
  • GILUPI GmbH
  • iCellate Medical AB
  • Ikonisys, Inc.
  • IVDiagnostics, LLC
  • Miltenyi Biotec GmbH
  • On-chip Biotechnologies
  • Oncolys Biopharma Inc.
  • Parsortix/ANGLE plc
  • QIAGEN N.V.
  • RareCells Diagnostics
  • RareCyte, Inc.
  • ScreenCell
  • Silicon Biosystems
  • SRI Biosciences
  • Vitatex Inc.
  • Vortex Biosciences

圖表清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: KLI5593376

Circulating tumor cells (CTCs) have tremendous utility in cancer research, aiding researchers in deciphering the complex processes leading to cancer metastasis and in developing more effective cancer therapeutics. Besides the research applications, the detection and analysis of CTCs has enormous potential in the diagnosis and management of cancer, as current tools, such as tumor tissue biopsy or imaging technologies, have numerous limitations. Although their biology and characteristics are still not entirely elucidated, CTCs are believed to detach from primary or secondary tumors, enter the bloodstream, and travel to distant organs. The majority of CTCs die in the bloodstream due to the harsh environment; very few of them are able to metastasize, and even fewer - known as cancer stem cells (CSCs) - can form distant tumors. Nevertheless, this small percentage of CTCs - about 0.01% - is sufficient to initiate and continue the blood-borne metastasis process, which leads to the progression of the disease and death.

The Market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) is a detailed analysis of the potential opportunities for manufacturers of CTCs-based technologies, informing readers of the scientific basis of CTCs in an understandable fashion and constructing models of revenue opportunity based on several dimensions - application area, cancer type and region - that can assist with business planning efforts.

The report provides data on the following:

  • Industry Structure - Selected Competitors and Marketed Products, 2014
  • CellSearch System (IVD Use) Analysis, 2015
  • AdnaTest (IVD Use) Analysis, 2015
  • Significant Trends in the CTCs Market, 2015
  • Estimated Market Breakdown, 2014 (Research Segment, Diagnostics Segment)
  • Estimated Market Breakdown by Type of Cancer, 2014
  • Estimated Market Breakdown by Geographic Region, 2014
  • Global Revenues and Forecast for the CTCs Market by Application, 2013-2015 and 2019
  • Global Revenues for the CTCs Market by Geographic Region, 2013-2015 and 2019

The global market for technologies serving CTCs research and diagnostics is experiencing several notable trends that have a significant effect on its participants, as well as on the overall market growth. The report presents analysis of such trends, including:

  • Increasing Incorporation of CTCs Technologies in Clinical Trials to Accelerate Market Growth
  • The Quest for Personalized Medicine to Spur the Use of CTCs in Research & Development
  • Increasing Development of CTC-based Diagnostics Tests to Augment Market Revenues
  • Increasing Global Incidence of Cancer and Life Expectancy to Increase Testing Volumes
  • The Impact of Clinical Utility on Adoption of CTCs Tests in Clinical Practice
  • The Impact of New Technologies Approved by Regulatory Agencies on Market Growth
  • The Impact of Insurance Coverage on Utilization and Market Revenues

The report also covers notable industry events such as:

  • CTCs Enumeration by CellSearch Demonstrating Potential as an Efficacy-Response Surrogate
  • The Menarini Group Acquisition of Silicon Biosystems
  • Cynvenio Biosystems' Launch of the ClearID Breast Cancer Monitoring Test
  • Vitatex's Licensing of Cell Adhesion Matrix Technology to Noble Life Sciences
  • Janssen Diagnostics and Asuragen's Introduction of NGS technology for CellSearch

The global market for CTC detection, isolation and analysis devices is a heterogeneous and competitive market, constantly driven by technological innovation and demand for improved technologies. The market includes numerous competitors with different capabilities. These numerous specialized or research-based companies also develop and commercialize products for the detection, isolation and analysis of CTCs, and contribute considerably to the technological advancements in this field. As part of its extensive coverage, the report profiles several competitors in the market.

The following companies are profiled:

  • Janssen Diagnostics
  • AdnaGen AG (currently QIAGEN Hannover GmbH)
  • Acousys Biodevices, Inc.
  • Advanced Cell Diagnostics, Inc.
  • ApoCell, Inc.
  • BioCEP Ltd.
  • Biocept, Inc.
  • Biofluidica
  • BioView Ltd.
  • Clearbridge Biomedics Pte Ltd
  • Creatv MicroTech, Inc.
  • Cynvenio Biosystems
  • CytoTrack ApS
  • DeNovo Sciences Inc.
  • Epic Sciences
  • Fluidigm Corporation
  • Fluxion Biosciences
  • GILUPI GmbH
  • iCellate Medical AB
  • Ikonisys, Inc.
  • IVDiagnostics, LLC
  • Miltenyi Biotec GmbH
  • On-chip Biotechnologies
  • Oncolys Biopharma Inc.
  • Parsortix/ANGLE plc
  • QIAGEN N.V.
  • RareCells Diagnostics
  • RareCyte, Inc.
  • ScreenCell
  • Silicon Biosystems
  • SRI Biosciences
  • Vitatex Inc.
  • Vortex Biosciences

Table of Contents

ONE: EXECUTIVE SUMMARY

  • Circulating Tumor Cells in Cancer
  • Current and Potential Clinical Applications of CTCs
  • CTCs Detection, Isolation and Analysis Technologies
  • Industry and Market Structure

TWO: CANCER OVERVIEW

  • Disease Overview
  • Risk Factors
  • Prevalence and Incidence of Cancer

THREE: CIRCULATING TUMOR CELLS OVERVIEW

  • Overview
  • CTCs Applications
  • Characteristics of CTCs
  • CTCs Isolation and Characterization Challenges
  • Current Markers for CTCs Identification and Analysis
  • Epithelial Cell Adhesion Molecule (EpCAM)
  • Ephrin Receptor B4 (EpB4)
  • Epidermal Growth Factor Receptor (EGFR)
  • Human Epidermal Growth Factor (HER2)
  • Mucin-1 (MUC-1)
  • Carcinoembryonic Antigen (CEA)
  • Cytokeratins
  • Other CTCs Markers Investigated for Clinical Applications
  • Cyclophilins
  • Plastin3 (PLS3)
  • Vimentin
  • Conclusions
  • Current and Potential Clinical Applications of CTCs
  • Prognostic Tool for Survival
  • Non-Invasive Early Diagnosis of Cancer
  • Predictors of Disease Evolution and Metastatic Potential
  • Therapy Guidance and Monitoring/ Predictor of Response to Therapy
  • Patient Stratification in Clinical Trials
  • Surrogate Endpoint in Clinical Trials
  • Drug Development - Selection of Drug Targets

FOUR: CTCs ISOLATION AND DETECTION TECHNOLOGIES

  • Overview
  • Enrichment Methods Based on Physical Properties
  • Size-based Methods
  • Density-based Methods
  • Electrophysiological-based Methods
  • Immuno-Mediated Capture Methods
  • Magnetic Platforms
  • Microfluidic Platforms
  • Conclusion
  • Optical Identification and Enumeration
  • Bioview's Duet Cell Imaging System (Israel)
  • CytoTrack's Optical Scanning Technology (Denmark)
  • Epic Sciences (San Diego, California, USA)
  • Ikonisys (New Haven, CT, USA)
  • Nucleic Acid-based CTC Detection Methods
  • RNAscope (Advanced Cell Diagnostics, USA)
  • Cytometric Detection and Enumeration Methods
  • FASTcell Cytometer (SRI Biosciences, USA)
  • On-chip Sort Cell Sorter (On-chip Biotechnologies, Japan)
  • Other CTCs Isolation and Detection Approaches
  • Virus Vectors Fluorescence
  • Selectin-Mediated Capture
  • Cell Adhesion Matrix
  • Other Combination Negative Depletion/ Positive Selection Methods
  • Rheology-based Methods
  • In Vivo Detection Methods

FIVE: INDUSTRY AND MARKET LANDSCAPE

  • Industry Structure
  • Competitive Factors
  • Products Analysis
  • CellSearch
  • AdnaTests
  • Significant Market Trends
  • Increasing Incorporation of CTCs Technologies in Clinical Trials to Accelerate
  • Market Growth
  • The Quest for Personalized Medicine to Spur the Use of CTCs in Research & Development
  • Increasing Development of CTC-based Diagnostics Tests to Augment Market Revenues
  • Increasing Global Incidence of Cancer and Life Expectancy to Increase Testing Volumes
  • The Impact of Clinical Utility on Adoption of CTCs Tests in Clinical Practice
  • The Impact of New Technologies Approved by Regulatory Agencies on Market Growth
  • The Impact of Insurance Coverage on Utilization and Market Revenues
  • Notable Industry Events
  • CTCs Enumeration by CellSearch Demonstrated Potential as Efficacy-Response Surrogate
  • The Menarini Group Acquired Silicon Biosystems
  • Cynvenio Biosystems Launched ClearID Breast Cancer Monitoring Test
  • Vitatex Licenses Cell Adhesion Matrix Technology to Noble Life Sciences
  • SWOG S0500 Clinical Trial Results Presented in December 2013
  • Parsorter PS1 Launched to Market in Europe
  • Clearbridge Biomedics Launched the ClearCell FX System for Capturing CTCs in Whole Blood Samples
  • Fluxion Biosciences Launched Next Generation Sequencing Assay Kits for IsoFlux System
  • Janssen Diagnostics and Asuragen Introduce NGS technology for CellSearch
  • Biocept Collaborates with Rosetta Genomics to Evaluate CTCs' microRNA
  • Biocept Launches Lung Cancer CTC Tests
  • Parsortix Collaborates with EKF Diagnostics and Undisclosed Pharmaceutical
  • Company to Develop “Liquid Biopsy” Applications
  • ThermoFisher Scientific Enters into Distribution Agreement with Cynvenio
  • Biosystems for LiquidBiopsy Platform
  • QIAGEN Acquired AdnaGen's CTC's Technology
  • Total Market Revenues and Forecast
  • Market Snapshot
  • Total Market Forecast

SIX: COMPANY PROFILES

  • Janssen Diagnostics
  • AdnaGen AG (currently QIAGEN Hannover GmbH)
  • Acousys Biodevices, Inc.
  • Advanced Cell Diagnostics, Inc.
  • ApoCell, Inc.
  • BioCEP Ltd.
  • Biocept, Inc.
  • Biofluidica
  • BioView Ltd.
  • Clearbridge Biomedics Pte Ltd
  • Creatv MicroTech, Inc.
  • Cynvenio Biosystems
  • CytoTrack ApS
  • DeNovo Sciences Inc.
  • Epic Sciences
  • Fluidigm Corporation
  • Fluxion Biosciences
  • GILUPI GmbH
  • iCellate Medical AB
  • Ikonisys, Inc.
  • IVDiagnostics, LLC
  • Miltenyi Biotec GmbH
  • On-chip Biotechnologies
  • Oncolys Biopharma Inc.
  • Parsortix/ANGLE plc
  • QIAGEN N.V.
  • RareCells Diagnostics
  • RareCyte, Inc.
  • ScreenCell
  • Silicon Biosystems
  • SRI Biosciences
  • Vitatex Inc.
  • Vortex Biosciences

LIST OF EXHIBITS

TWO: CANCER OVERVIEW

  • Table 2-1: Top Ten Causes of Death in the World by Geographic Region, 2012
  • Table 2-2: Top Ten Causes of Death in the World, 2012
  • Table 2-3: Projected Top Ten Causes of Death in the World, 2015
  • Table 2-4: Projected Top Ten Causes of Death in the World in High Income Countries, 2015
  • Table 2-5: Projected Top Ten Causes of Death in the World in Upper Middle Income Countries, 2015
  • Table 2-6: Global Incidence of Cancer by Geographic Region, 2012
  • Table 2-7: Global Incidence of the Five Most Common Types of Cancer in Men,2012
  • Table 2-8: Global Incidence of the Five Most Common Types of Cancer in Women, 2012
  • Table 2-9: Global Incidence of Most Common Types of Cancer in Both Genders,2012
  • Table 2-10: Projected Growth in Global Incidence of Cancer by Geographic Region, 2012-2030

THREE: CIRCULATING TUMOR CELLS OVERVIEW

  • Table 3-1: Typical Human Blood Cellular Composition
  • Table 3-2: Challenges in the Detection and Isolation of CTCs, 2015
  • Table 3-3: Selected Markers for CTCs Identification and Analysis
  • Table 3-4: Selected EpCAM-based Methods
  • Table 3-5: Current and Potential Clinical Uses of CTCs, 2015

FOUR: CTCs ISOLATION AND DETECTION TECHNOLOGIES

  • Table 4-1: Selected Size-Based CTCs Enrichment Methods
  • Table 4-2: Selected Density-Based CTCs Enrichment Methods
  • Table 4-3: Selected CTCs Detection and Isolation Methods Based on Electrophysiological Properties
  • Table 4-4: Selected CTCs Magnetic Platforms Based on Cell Surface Markers
  • Table 4-5: Selected CTCs Immunomagnetic Microfluidics Platforms
  • Table 4-6: Selected CTCs Optical Identification Methods
  • Table 4-7: Selected Nucleic Acid-based CTCs Detection Methods
  • Table 4-8: Comparison of Selected Cytometric CTCs Detection Methods
  • Table 4-9: Selected CTCs In Vivo Detection Platforms

FIVE: INDUSTRY AND MARKET LANDSCAPE

  • Table 5-1: Industry Structure - Selected Competitors and Marketed Products, 2014
  • Table 5-2: CellSearch System (IVD Use) Analysis, 2015
  • Table 5-3: AdnaTest (IVD Use) Analysis, 2015
  • Table 5-4: Significant Trends in the CTCs Market, 2015
  • Figure 5-1: Estimated Market Breakdown, 2014 (Research Segment, Diagnostics Segment)
  • Figure 5-2: Estimated Market Breakdown by Type of Cancer, 2014 (Breast, Prostate, Colorectal, Lung, Others)
  • Figure 5-3: Estimated Market Breakdown by Geographic Region, 2014 (US, EU, ROW)
  • Table 5-5: Global Revenues and Forecast for the CTCs Market by Application, 2013-2015 and 2019 (Diagnostics Segment, Research Segment, Total Market)
  • Figure 5-4: Global Revenues and Forecast for the CTCs Market, 2013-2015 and 2019 (Diagnostics Segment, Research Segment, Total Market)
  • Table 5-6: Global Revenues for the CTCs Market by Geographic Region, 2013-2015 and 2019 (US Market, EU Market, ROW Market, Total Market)
  • Figure 5-5: Global Revenues for the CTCs Market by Geographic Region, 2013- 2015 and 2019 (US Market, EU Market, ROW Market, Total Market)
Back to Top